A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

计划入组 265 人 · 首次发布于 2018 年 5 月 29 日

Phrenic Nerve and Diaphragm Electrophysiology in Pompe Disease

计划入组 20 人 · 首次发布于 2026 年 6 月 24 日

Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

计划入组 45 人 · 首次发布于 2025 年 8 月 14 日

POMHEX

PSMADex

SomaDex

Universitat Pompeu Fabra

Spain

Powder Pharmaceuticals Incorporated

Virgin Islands (British)

PROUDEX PHARMACEUTICALS PTY LTD

Australia

GSK's Blenrep Receives Breakthrough Therapy Designation in China and Japan Review for Multiple Myeloma

FDA Accepts GSK's Blenrep Combination Therapy for Relapsed/Refractory Multiple Myeloma

FDA Accepts GSK's Blenrep Combinations for Relapsed/Refractory Multiple Myeloma Treatment